Article
Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
Cancer control : journal of the Moffitt Cancer Center - 1 Jan 2000
Liao Jun, Huang Yihua, Gan Jiadi, Pang Lanlan, Ali Wael A S, Yang Yunpeng, Chen Likun, Zhang Li, Fang Wenfeng
Abstract excerpt
OBJECTIVES: Osimertinib has exhibited promising central nervous system (CNS) efficacy in Epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients. In real-world clinical practice, patients would turn to plasma genotyping or take osimertinib blindly after CNS progression on previous tyrosine kinase inhibitors (TKIs). However, the efficacy of osimertinib in those patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.